ArticleGynecologic oncology reports2026
Primary endometrial squamous cell carcinoma with molecular Characterization: A case report.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary endometrial squamous cell carcinoma (PESCC) is an extremely rare malignancy and represents a diagnostic challenge due to its histologic and immunophenotypic overlap with cervical squamous cell carcinoma involving the endometrium. Data regarding its molecular characteristics and their relevance to the 2023 FIGO molecular-integrated staging system remain limited.Case Presentation: We describe a postmenopausal woman presenting with abnormal uterine bleeding. The initial pathological interpretation suggested cervical intraepithelial neoplasia grade 3. However, repeat hysteroscopy and endocervical curettage did not identify a primary cervical lesion, supporting an endometrial origin. The patient underwent total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node mapping. Final pathology confirmed moderately differentiated PESCC with superficial myometrial invasion. Immunohistochemistry demonstrated diffuse squamous marker expression and limited hormone receptor positivity. Molecular testing showed microsatellite stability, absence of POLE mutation, and abnormal p53 expression, corresponding to FIGO 2023 stage IICm-p53abn. Conclusion: Current evidence suggests that PESCC may exhibit molecular and immunophenotypic features that differ from conventional endometrial adenocarcinoma; however, available data remain sparse. Further accumulation of molecularly characterized cases is necessary to clarify its biological behavior and staging implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.